Finding the way in the jungle of kinase drug targets

Drug Discovery Today: Technologies

Volumn 4, Issue 3-4, 2007, Pages

  Oxelmark, Ellinor ^a   Hornberg, Jorrit J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLT3 LIGAND; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN TYROSINE KINASE; SORAFENIB; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COMPUTER SIMULATION; DRUG SELECTIVITY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 68049137636     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2008.07.001     Document Type: Review

References (39)

1. O'neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5 (2006) 549-563
2. Sebolt-Leopold J.S., and English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 441 (2006) 457-462
3. Shawver L.K., et al. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 (2002) 117-123
4. Collins I., and Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2 (2006) 689-700
5. Giamas G., et al. Protein kinases as targets for cancer treatment. Pharmacogenomics 8 (2007) 1005-1016
6. Kamb A., et al. Why is cancer drug discovery so difficult?. Nat. Rev. Drug Discov. 6 (2007) 115-120
7. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715
8. Butcher E.C. Can cell systems biology rescue drug discovery?. Nat. Rev. Drug Discov. 4 (2005) 461-467
9. Kumar N., et al. Applying computational modeling to drug discovery and development. Drug Discov. Today 11 (2006) 806-811
10. Hornberg J.J., et al. Cancer: a Systems Biology disease. Biosystems 83 (2006) 81-90
11. Hahn W.C., et al. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
12. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
13. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
14. Futreal P.A., et al. A census of human cancer genes. Nat. Rev. Cancer 4 (2004) 177-183
15. Bhalla U.S., and Iyengar R. Emergent properties of networks of biological signaling pathways. Science 283 (1999) 381-387
16. Milo R., et al. Network motifs: simple building blocks of complex networks. Science 298 (2002) 824-827
17. Bhalla U.S., et al. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 297 (2002) 1018-1023
18. Hornberg J.J., et al. Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4 beta-phorbol 12-myristate 13-acetate. Eur. J. Biochem. 271 (2004) 3905-3913
19. Huang C.Y., and Ferrell Jr. J.E. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10078-10083
20. Kholodenko B.N. Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. Eur. J. Biochem. 267 (2000) 1583-1588
21. Ninfa A.J., and Mayo A.E. Hysteresis vs. graded responses: the connections make all the difference. Sci. STKE 2004 (2004) e20
22. Kholodenko B.N. Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 7 (2006) 165-176
23. Pouyssegur J., and Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur. J. Biochem. 270 (2003) 3291-3299
24. Kholodenko B.N. MAP kinase cascade signaling and endocytic trafficking: a marriage of convenience?. Trends Cell Biol. 12 (2002) 173-177
25. Folkman J. Angiogenesis. Annu. Rev. Med. 57 (2006) 1-18
26. McInnes I.B., and Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7 (2007) 429-442
27. Kacser H., and Burns J.A. The control of flux. Symp. Soc. Exp. Biol. 27 (1973) 65-104
28. Hornberg J.J., et al. Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. FEBS J. 272 (2005) 244-258
29. Kahn D., and Westerhoff H.V. Control theory of regulatory cascades. J. Theor. Biol. 153 (1991) 255-285
30. Heinrich R., et al. Mathematical models of protein kinase signal transduction. Mol. Cell 9 (2002) 957-970
31. Lee E., et al. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 1 (2003) E10
32. Ihekwaba A.E., et al. Sensitivity analysis of parameters controlling oscillatory signalling in the NF-kB pathway the roles of IKK and IkBa. Syst. Biol. 1 (2007) 93-103
33. Hornberg J.J., et al. Control of MAPK signalling: from complexity to what really matters. Oncogene 24 (2005) 5533-5542
34. Cascante M., et al. Metabolic control analysis in drug discovery and disease. Nat. Biotechnol. 20 (2002) 243-249
35. Hornberg J.J., et al. Metabolic control analysis to identify optimal drug targets. Prog. Drug Res. 64 (2007) 171-173 189
36. Hornberg J.J., and Westerhoff H.V. Oncogenes are to lose control on signaling following mutation: should we aim off target?. Mol. Biotechnol. 34 (2006) 109-116
37. Wan P.T., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
38. Snoep J.L. The silicon cell initiative: working towards a detailed kinetic description at the cellular level. Curr. Opin. Biotechnol. 16 (2005) 336-343
39. Alkema W., et al. Target validation in silico: does the virtual patient cure the pharma pipeline?. Expert. Opin. Ther. Targets 10 (2006) 635-638